Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

7.7K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

An encyclopedia of human enhancer-gene regulatory interactions.

Nature·2026
Same author

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma.

Blood·2026
Same author

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same author

<i>SPP1</i><sup>hi</sup> macrophages in fibrin niches promote hyperplastic tissue remodeling in rheumatoid arthritis synovium.

Science translational medicine·2026
Same author

Urolithiasis in patients with cancer.

Nature reviews. Urology·2026

相关实验视频

Updated: Feb 28, 2026

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.5K

敏感的CAR-T细胞在固体瘤中重新定义可向的CD70表达.

Sophie A Hanina1, Tyler Park2, Michael Lopez1

  • 1Columbia Initiative in Cell Engineering and Therapy (CICET), Department of Medicine, Columbia University Irving Medical Center, Columbia University, New York, NY USA.

Science (New York, N.Y.)
|February 26, 2026
PubMed
概括

固体瘤抗原的异质性对嵌合抗原受体 (CAR) T细胞疗法构成了挑战. 一种新的HLA独立T细胞 (HIT) 受体有效地准CD70表达的固体瘤,克服了当前CAR T细胞的局限性.

更多相关视频

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.2K
A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

17.4K

相关实验视频

Last Updated: Feb 28, 2026

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.5K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.2K
A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

17.4K

科学领域:

  • 在瘤学瘤学.
  • 免疫学 免疫学 免疫学
  • 生物技术是生物技术.

背景情况:

  • 固体瘤抗原异质性对有效的癌症免疫疗法构成重大障碍,特别是对于仿真抗原受体 (CAR) T 细胞.
  • 在重要正常组织中缺乏具有限制表达的通用瘤抗原,使固体瘤治疗策略复杂化.
  • 鉴于CD70在免疫细胞中的生理表达有限,以及在各种癌症中的异常上调,CD70被确定为一个有前途的标.

研究的目的:

  • 解决癌症免疫治疗中固体瘤抗原异质性的挑战.
  • 研究CD70作为T细胞治疗的泛癌点的潜力.
  • 开发和评估一种新的T细胞受体策略,用于向固体瘤中异质CD70表达.

主要方法:

  • 在实体瘤中研究了CD70表达异质性的表观遗传调节.
  • 开发了一个高度敏感的CD70向的HLA独立T细胞 (HIT) 受体.
  • 设计了HIT受体,以共同表达共刺激分子CD80和4-1BBL,以增强T细胞激活.

主要成果:

  • 证明CD70表达在固体瘤中是表观遗传调节,导致显著的异质性.
  • 展示了传统的检测方法可能无法识别低CD70表达细胞.
  • 通过开发的HIT受体确认了CD70异质瘤的有效消除,其表现优于原型CAR T细胞.

结论:

  • 开发的HIT受体策略为克服固体瘤中抗原异质性的潜在解决方案.
  • 这种方法可能能够有效地治疗广泛的固体瘤,这些瘤以前不耐免疫治疗.
  • 突出了针对固体瘤中CD70等表观遗传调节抗原的治疗潜力.